Global Gene Therapy Market By Vector Type (Viral Vector and Non Viral Vector ), By Therapy ( In Vivo Therapy and Ex Vivo Therapy ), By Gene Type (Antigen , Cytokine , Tumor Suppressor , Suicide , Deficiency ,Growth factors ,Receptors , Others),By Application (Oncological Disorders , Rare Diseases , Neurological Disorders, Other Diseases, and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East and Africa) – Global and Regional Industry Overview, Market Intelligence, Comprehensive Analysis, Historical Data and Forecasts 2022 – 2028

Global Gene Therapy Market Overview

A gene is a functioning hereditary unit of life that contains instructions for performing a certain function. The advanced treatment for cancer, chronic disease, infectious disease, and blood diseases is gene therapy. To treat or prevent disease progression, doctors use gene therapy to replace faulty genes in a patient's body with healthy ones.

Globally, a growth in the occurrence of chronic conditions such as cancer, rare disease genetic disorders, and others is driving the Gene Therapy Market Growth. Furthermore, increased government backing, ethical acceptance of gene therapy for cancer treatment, and an increase in cancer prevalence all contribute to the market's growth. Gene Therapy Market Opportunity is also provided by an increase in healthcare expenditure, the development of improved healthcare infrastructure, and the availability of reimbursements. During the projection period, however, the high cost of gene treatments is expected to limit market growth to some extent. In the future years, the gene therapy industry is likely to be guided by the expanding usage of gene modification in a number of treatments, as well as the increasing use of genome editing in biotechnology applications. High gene therapy prices and a lack of uniformity are predicted to stymie the worldwide gene therapy business.

Market Size

According to Business Intelligence Insights “Global Gene Therapy Market" is expected to grow from USD 4029.50 million  in 2021 to USD 15594.00 million by 2028, at a CAGR of 25.30% during the forecast period 2022-2028

Covid -19 Impact Analysis

COVID-19 has had a negative influence on the gene therapy market as a result of a decrease in the number of cancer patients visiting hospitals and clinics for gene therapy (ICI), which has resulted in a decrease in demand for gene therapy products. According to the NCBI, cancer care in the United States is expected to drop by 50% in 2020, and overall cancer therapies are expected to drop by 50% during COVID-19, resulting in a drop in demand for gene therapy goods on the market.

Market Dynamics

•    Drivers

o    A rise in the global prevalence of chronic diseases like cancer, uncommon disease genetic disorders, and others. 
o    The growth in government funding, as well as ethical acceptance of gene therapy for cancer treatment, are all positive factors.

•    Restraints

o    Standardization is lacking.
o    Product Costs are Expensive.

Segmentation Insights

The global Gene Therapy market is divided into vector type, therapy, gene type, application, and region. On the basis of Vector Type the market is segregated into Viral Sector And Non Viral Sector. Based on Therapy, the market is categorized into In Vivo Therapy and Ex Vivo Therapy. On the basis of Gene Type, the global market is segregated as Antigen , Cytokine , Tumor Suppressor , Suicide , Deficiency ,Growth factors ,Receptors ,Others. Moreover, on the basis of mode of application Oncological Disorders , Rare Diseases ,Neurological Disorders ,Other Diseases.

Non Viral dominated the market with more than 50% of the market share

In 2021, the market for Gene Therapy was dominated by non viral sector. The non-viral vector category accounts for the greatest share of the Gene Therapy Market and is expected to grow at the fastest rate over the forecast period. The rise in the incidence of cancer and other target diseases, as well as the availability of reimbursement policies and increased financing for gene therapy research, are all expected to drive market expansion in the future years.

Oncology Disorders dominated the market with more than 20% of the market share

The mode of application in which Gene Therapy can be taken are Oncological Disorders, Rare Diseases, Neurological Disorders, Other Diseases. In the worldwide Gene Therapy industry, oncology disorders are the most popular application.The rising burden of cancer, the increased emphasis on research to create an effective cancer treatment, and rising cancer research investments are all driving the segment's rise. Globocan 2020 estimates that there will be 19,292,789 new cancer cases and 9,958,133 cancer deaths globally in 2020. In the treatment of cancer, many gene therapy strategies are currently being used. Anti-angiogenic gene therapy, pro-drug activating suicide gene therapy, immunological modulation based on gene therapy, oncolytic virotherapy, gene defect correction/compensation, antisense, genetic manipulation of apoptotic and tumour invasion pathways, and RNAi techniques are only a few of the options. Lung, brain, breast, pancreas, liver, colorectal, prostate, bladder, head & neck, skin, renal, and ovarian cancers have all been targeted by these medicines.

By Vector Type 
•    Viral Vector 
•    Non Viral Vector

By Therapy 
•    In Vivo Therapy 
•    Ex Vivo Therapy 

By Gene Type 
•    Antigen 
•    Cytokine 
•    Tumor Suppressor 
•    Suicide 
•    Deficiency 
•    Growth factors 
•    Receptors 
•    Others 

By Application 
•    Oncological Disorders 
•    Rare Diseases 
•    Neurological Disorders 

Other Diseases
•    Vitamins
•    Minerals
•    Amino Acids
•    Enzymes
•    Probiotics
•    Other Gene Therapy

By Region
•    North America
o    U.S.
o    Canada
•    Europe 
o    Germany
o    U.K.
o    France
o    Italy
o    Spain
o    Rest of Europe
•    Asia Pacific 
o    China
o    India
o    Japan
o    Rest of Asia Pacific
•    Latin America 
o    Brazil
o    Mexico
o    Rest of Latin America
•    Middle East and Africa 
o    UAE
o    South Africa
o    Rest of Middle East and Africa (MEA)

Key Players

•    Novartis AG
•    Gilead Sciences.
•    Jazz Pharmaceuticals
•    Orchard Therapeutics.
•    Bristol-Myers Squibb.
•    Amgen Inc.
•    Shenzhen SiBiono Genentech
•    Shanghai Sunway Biotech Co., Ltd.
•    Adaptimmune Therapeutics plc
•    Adverum Biotechnologies, Inc
•    Abeona Therapeutics Inc.
•    Applied Genetic Technologies Corporation
•    Amgen Inc.
•    Astellas Therapeutics, Inc.
•    Bluebird Bio, Inc.
•    CRISPR Therapeutics AG
•    Intellia Therapeutics, Inc.
•     REGENXBIO Inc.
•    Sangamo Therapeutics, Inc.
•    Unique N. V.
•    Voyager Therapeutics, Inc
•    Merck and Co Inc.
•    Dendron Corporation. 

Regional Insights

North America dominated the market with more than 55% of the market share

The North American regional market will lead the industry and grow at the fastest CAGR over the forecast year. A robust regulatory framework for fostering the development of cellular treatment, as well as the presence of a large number of biopharma businesses, has prompted several government bodies to invest in the region. As a result, the regional market is moving forward. The existence of gene therapy research and development centres and institutions is projected to propel the market in North America. In addition, rising chronic disease incidence, rising healthcare spending, the presence of modern healthcare infrastructure, and the availability of reimbursements are all important drivers driving market expansion. On the other hand, the approval of Zolgensma in 2019 has considerably helped the US market. Despite the price disputes, the product is predicted to grow at a profit in the forecast period.

Table

Report Attributes	Details
Market Size Value in 2021	USD 4029.50 million
Market Size Value in 2028	USD 15594.00 million
Growth Rate	+25.30%
Base Year	2021
Forecast Period	2022-2028
Historical Data	2018-2020
Forecast Units	USD million
Countries Covered	North America: U.S., Canada, Europe: Germany, U.K., France, Italy, Spain, Rest of Europe, Asia Pacific: China, India, Japan, Rest of Asia Pacific, Latin America: Brazil, Mexico, Rest of Latin America, Middle East and Africa: UAE, South Africa, Rest of Middle East and Africa (MEA)
Segments Covered	By Vector Type, By Therapy, By Gene Type, By Application, Other Diseases, By Region
Competitive landscape	Leading companies, Competitive strategies and Consumer engagement scope
Customization is available	If our report does not contain the information you require, you can contact our experts to have segments created for you. Please contact us at sales@businessintelligence-insights.com if you have any questions

 

Frequently Asked Questions (FAQ):